Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis

作者：Yifan Meng, Wanrong Lu, Ensong Guo, Jia Liu, Bin Yang, Ping Wu, Ping Wu, Shitong Lin, Ting Peng, Yu Fu, Fuxia Li, Zizhuo Wang, Yuan Li, Rourou Xiao, Chen Liu, Yuhan Huang, Xue Yan Wu, Xue Yan Wu, Lixin You, Ding Ma, Chaoyang Sun, Peng Wu, Peng Wu, Gang Chen · 发表于：Journal of Hematology & Oncology · 年份：2020 · DOI：10.1186/s13045-020-00907-0 · 被引用次数：197 · 研究领域：COVID-19 and healthcare impacts、COVID-19 Clinical Research Studies、Long-Term Effects of COVID-19

BACKGROUND: Although research on the effects of comorbidities on coronavirus disease 2019 (COVID-19) patients is increasing, the risk of cancer history has not been evaluated for the mortality of patients with COVID-19. METHODS: In this retrospective study, we included 3232 patients with pathogen-confirmed COVID-19 who were hospitalized between January 18th and March 27th, 2020, at Tongji Hospital in Wuhan, China. Propensity score matching was used to minimize selection bias. RESULTS: In total, 2665 patients with complete clinical outcomes were analyzed. The impacts of age, sex, and comorbidities were evaluated separately using binary logistic regression analysis. The results showed that age, sex, and cancer history are independent risk factors for mortality in hospitalized COVID-19 patients. COVID-19 patients with cancer exhibited a significant increase in mortality rate (29.4% vs. 10.2%, P < 0.0001). Furthermore, the clinical outcomes of patients with hematological malignancies were worse, with a mortality rate twice that of patients with solid tumors (50% vs. 26.1%). Importantly, cancer patients with complications had a significantly higher risk of poor outcomes. One hundred nine cancer patients were matched to noncancer controls in a 1:3 ratio by propensity score matching. After propensity score matching, the cancer patients still had a higher risk of mortality than the matched noncancer patients (odds ratio (OR) 2.98, 95% confidence interval (95% CI) 1.76-5.06). Addition...